

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/528,978		03/21/2000	R. Scott Obach	PC10244A	7527	
23913	7590	06/05/2002				
PFIZER II	NC		EXAMINER			
150 EAST 5TH FLOC	R - STOP	49	JIANG, SHAOJIA A			
NEW YORK, NY 10017-5612				ART UNIT	PAPER NUMBER	
			1617			
				DATE MAILED: 06/05/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)					
•	•		9/528,978 OBACH, R. SCOTT						
	Office Action Summary	Examiner		Art Unit					
	•	Shaojia A. Jiang	:	1617					
	The MAILING DATE of this communication app		sheet with the co		s				
Period for Reply									
THE I - External after - If the - If NC - Failu - Any I	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we re to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however within the statutory minim will apply and will expire SI cause the application to b	er, may a reply be time num of thirty (30) days X (6) MONTHS from the pecome ABANDONED	ely filed will be considered timely. ne mailing date of this commur (35 U.S.C. § 133).	nication.				
1)	Responsive to communication(s) filed on 18 M	March 2002							
2a)⊠	·	is action is non-fina	al						
3)□	<b>,—</b>			secution as to the me	erits is				
,—	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
· -	on of Claims								
·	Claim(s) <u>1,6 and 11</u> is/are pending in the appli		•						
	4a) Of the above claim(s) is/are withdrawn from consideration.								
·	Claim(s) is/are allowed.								
·	Claim(s) <u>1,6 and 11</u> is/are rejected.								
	Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	r alaatiaa raquiram	ont						
•	on Papers	election requirem	cit.						
	The specification is objected to by the Examine	r.							
10)	The drawing(s) filed on is/are: a)☐ accep	oted or b) objected	d to by the Exan	niner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11) 🗌	The proposed drawing correction filed on	_is: a)□ approved	l b)□ disapprov	ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority ι	ınder 35 U.S.C. §§ 119 and 120								
13)[	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)	a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
* 5	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
	)  The translation of the foreign language pro Acknowledgment is made of a claim for domesti								
Attachmen	t(s)								
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 N	-	(PTO-413) Paper No(s) atent Application (PTO-152					

Art Unit: 1617

## **DETAILED ACTION**

This Office Action is a response to Applicant's amendment and response filed on March 18, 2002 in Paper No. 7 wherein claims 2-5, 7-10, 12-13, and 14-22 are cancelled and claim 1 has been amended. Currently, claims 1, 6, and 11 are pending in this application.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 6, and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Benet et al. (5,567,592) and Hess (WO 96/14845) essentially for reasons of record stated in the Office Action dated August 14, 2001.

Applicant's remarks filed on March 18, 2002 in Paper No. 7 with respect to this rejection of claims 1, 4, 6, and 11 made under 35 U.S.C. 103(a) of record stated in the previous Office Action (August 14, 2001) have been fully considered but are not deemed persuasive as to the nonobviousness of the claimed invention over the prior art for the following reasons.

Applicant's assertion that the there is no motivation or suggestion whatsoever in the prior art to use the claimed combinations has been considered but is not found

persuasive. It has been held that it is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for same purpose in order to form a third composition that is to be used for the very same purpose; idea of combining them flows logically from their having been individually taught in prior art. In re Kerkhoven, 205 USPQ 1069, CCPA 1980. See MPEP 2144.06. In the instant case, as discussed in the previous Office Action, both NK-1 receptor antagonists including the elected species, (2S,3S)-2-phenyl-3-(2-methoxy-5-trifluoromethoxyphenyl)methylaminopiperidine, and quinidine are well known CYP2D6 substrates, as taught by Applicant's admission regarding the prior art in the instant specification (see page 4 lines 5-8 and 14-26). Moreover, as discussed in the previous Office Action, it is well known that CYP2D6 substrates mediate oxidative biotransformation for the major clearance mechanism in humans. Therefore, one of ordinary skill in the art would have reasonably expected that combining two particular CYP2D6 substrates (two instant elected species) known useful for the same purpose, i.e., mediating oxidative biotransformation for the major clearance mechanism in humans, in a composition to be administered would produce additive therapeutic effects to improve the same treatment, absent evidence to the contrary.

Page 3

Since all active composition components herein are known to useful to be CYP2D6 substrates, mediating oxidative biotransformation for the major clearance mechanism in humans, it is considered prima facie obvious to combine them into a single composition to form a third composition useful for the very same purpose. At Application/Control Number: 09/528,978

Art Unit: 1617

least additive therapeutic effects would have been reasonably expected based on the well settled principle set forth *In re Kerkhoven* regarding combination inventions.

Additionally, Applicant arguments that the examiner has made parallels with other enzyme, CYP3A, with CYP2D6, according to Benet's teaching regarding the combination of two CYP3A, have been considered but not found persuasive. Benet's teaching regarding the combination of two CYP3A have been cited by the examiner primarily for this teaching further provides motivation to employ the combination herein.

Therefore, motivation to combine the teachings of the prior art cited herein to make the present invention is seen. The claimed invention is clearly obvious in view of the prior art.

The record contains <u>no</u> clear and convincing evidence of nonobviousness or unexpected results for the combination herein over the prior art. In this regard, it is noted that the specification provides no <u>side-by-side</u> comparison with the closest prior art in support of nonobviousness for the instant claimed invention over the prior art.

For the above stated reasons, said claims are properly rejected under 35 U.S.C. 103(a). Therefore, said rejection is adhered to.

In view of the rejections to the pending claims set forth above, no claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 May 21, 2002

